Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue (2021 - 2026)

Kiniksa Pharmaceuticals International's Cost of Revenue history runs 6 years deep, the most recent figure standing at $20.8 million for Q1 2026.

• Quarterly Cost of Revenue rose 16.39% year-over-year to $20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.6 million (up 18.19% YoY) and the FY2025 annual result came in at $77.7 million, up 27.52% from the prior year.
• Cost of Revenue was $20.8 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $20.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $20.9 million in Q4 2025 and bottomed at $491000.0 in Q1 2023.
• A 5-year average of $12.3 million and a median of $10.6 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue plunged 88.36% — and 2024, when it soared 2055.4%.
• Kiniksa Pharmaceuticals International's Cost of Revenue stood at $6.7 million in 2022, then jumped by 42.83% to $9.6 million in 2023, then soared by 86.73% to $17.9 million in 2024, then rose by 17.04% to $20.9 million in 2025, then retreated by 0.71% to $20.8 million in 2026.
• Business Quant data shows KNSA's Cost of Revenue at $20.8 million in Q1 2026, $20.9 million in Q4 2025, and $20.3 million in Q3 2025.